Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19

J Infect. 2021 Jan;82(1):126-132. doi: 10.1016/j.jinf.2020.11.031. Epub 2020 Nov 28.

Abstract

Objectives: COVID-19 has caused a large global pandemic. Patients with COVID-19 exhibited considerable variation in disease behavior. Pervious genome-wide association studies have identified potential genetic variants involved in the risk and prognosis of COVID-19, but the underlying biological interpretation remains largely unclear.

Methods: We applied the summary data-based Mendelian randomization (SMR) method to identify genes that were pleiotropically associated with the risk and various outcomes of COVID-19, including severe respiratory confirmed COVID-19 and hospitalized COVID-19.

Results: In blood, we identified 2 probes, ILMN_1765146 and ILMN_1791057 tagging IFNAR2, that showed pleiotropic association with hospitalized COVID-19 (β [SE]=0.42 [0.09], P = 4.75 × 10-06 and β [SE]=-0.48 [0.11], P = 6.76 × 10-06, respectively). Although no other probes were significant after correction for multiple testing in both blood and lung, multiple genes as tagged by the top 5 probes were involved in inflammation or antiviral immunity, and several other tagged genes, such as PON2 and HPS5, were involved in blood coagulation.

Conclusions: We identified IFNAR2 and other potential genes that could be involved in the susceptibility or prognosis of COVID-19. These findings provide important leads to a better understanding of the mechanisms of cytokine storm and venous thromboembolism in COVID-19 and potential therapeutic targets for the effective treatment of COVID-19.

Keywords: Coronavirus disease 2019; Gene expression quantitative trait loci; IFNAR2; Summary Mendelian randomization.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aryldialkylphosphatase / genetics
  • Blood Coagulation / genetics
  • COVID-19 / epidemiology*
  • COVID-19 / mortality
  • Carrier Proteins / genetics
  • Cytokine Release Syndrome / genetics
  • Cytokine Release Syndrome / pathology
  • Genetic Predisposition to Disease / genetics
  • Genetic Variation / genetics*
  • Genome-Wide Association Study / methods*
  • Humans
  • Mendelian Randomization Analysis*
  • Prognosis
  • Receptor, Interferon alpha-beta / genetics
  • Risk
  • SARS-CoV-2 / genetics*
  • Venous Thromboembolism / genetics
  • Venous Thromboembolism / pathology

Substances

  • Carrier Proteins
  • HPS5 protein, human
  • IFNAR2 protein, human
  • Receptor, Interferon alpha-beta
  • Aryldialkylphosphatase
  • PON2 protein, human